Delivery Order SPE2DR25D1106-SPE2DR26FJC3D
- Not listed
- The Defense Logistics Agency awarded a $19,758.24 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on December 2, 2025, with an ultimate completion date of December 23, 2025. This competitively awarded, firm fixed-price contract is not set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The work will be performed at AmerisourceBergen's corporate office in Conshohocken,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $14,061.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), carries an ultimate completion date of September 3, 2025, and involves no set-aside designation....
- The Defense Logistics Agency awarded a $14,818.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectables on November 12, 2025, with completion targeted for December 4, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and reflects...
- The Defense Logistics Agency (DLA) awarded a $9,374.36 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on April 22, 2025, with completion scheduled for May 13, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,469.78. This is a firm fixed-price delivery order with no set-aside designation, to be completed by December 9, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,469.78 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors on November 20, 2025, with completion expected by December 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma,...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This firm fixed-price, competitively awarded contract (without set-aside designation) is scheduled for completion by August 13, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on September 28, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This competitively awarded, firm fixed-price contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order carries an ultimate completion date of October 20, 2025, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on August 27, 2025. This competitively awarded, firm fixed-price contract is a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to the company's location in Conshohocken,...
- SPE2DR25D1106Indefinite Delivery Contract
- SPE2DR25D1106-SPE2DR26FJC3DDelivery Order
The Defense Logistics Agency awarded a $19,758.24 firm fixed price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors on December 4, 2025, with completion targeted for December 26, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Tezspire is a biologic respiratory therapy used to treat moderate to severe eosinophilic or oral corticosteroid-dependent asthma, meeting medical supply needs for military healthcare systems and other federal beneficiaries. AmerisourceBergen Drug Corp maintains a substantial portfolio of federal pharmaceutical contracts with the Defense Logistics Agency's Medical Supply Chain, consistently winning competitively awarded orders for diverse pharmaceutical products including specialty medications, vaccines, and medical devices across multiple therapeutic domains. The company's designation as a prime vendor under the DLA Troop Support framework positions it as a critical supplier for military healthcare programs worldwide, with demonstrated capability to fulfill ranging from small-value transactions to substantial orders exceeding $45,000. This delivery order exemplifies the company's role in supporting the Defense Health Agency and broader federal healthcare missions through reliable pharmaceutical distribution.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.8k | 12/3/25 |